Profile data is unavailable for this security.
About the company
Silo Pharma, Inc. is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. The Company’s therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes programs, such as for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Its lead product candidate, SPC-15, is designed as a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for treatment of stress-induced psychiatric disorders such as PTSD and anxiety disorders. SPC-14 targets glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in Alzheimer’s disease. SPU-16 is a candidate targeting central nervous system (CNS) disorders, with an initial indication for multiple sclerosis.
- Revenue in USD (TTM)72.12k
- Net income in USD-5.08m
- Incorporated2023
- Employees--
- LocationSilo Pharma Inc677 N Washington BlvdSARASOTA 34236United StatesUSA
- Websitehttps://silopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Clearside Biomedical Inc | 3.33m | -26.00m | 3.40m | 32.00 | -- | -- | -- | 1.02 | -5.06 | -5.06 | 0.6461 | -10.31 | 0.1632 | -- | 6.32 | 104,031.30 | -127.43 | -67.79 | -160.28 | -84.94 | 88.07 | -- | -780.90 | -241.58 | -- | -- | 8.48 | -- | -79.77 | -5.20 | -5.75 | -- | 108.16 | -- |
| Indaptus Therapeutics Inc | 0.00 | -16.87m | 3.48m | 7.00 | -- | 0.5526 | -- | -- | -31.67 | -31.67 | 0.00 | 2.81 | 0.00 | -- | -- | 0.00 | -223.71 | -56.08 | -317.86 | -68.84 | -- | -- | -- | -- | -- | -13.74 | 0.00 | -- | -- | -- | 2.60 | -- | -- | -- |
| AIM ImmunoTech Inc | 112.00k | -15.75m | 3.51m | 21.00 | -- | -- | -- | 31.36 | -19.82 | -19.82 | 0.1067 | -2.20 | 0.0117 | -- | -- | 5,333.33 | -165.08 | -50.43 | -637.78 | -55.23 | 15.18 | -113.19 | -14,062.50 | -12,238.47 | -- | -- | -- | -- | -15.84 | 3.96 | 40.20 | -- | -45.22 | -- |
| Enveric Biosciences Inc | 0.00 | -11.25m | 3.66m | 5.00 | -- | 0.1661 | -- | -- | -94.63 | -94.63 | 0.00 | 15.83 | 0.00 | -- | -- | 0.00 | -212.68 | -146.94 | -262.78 | -198.90 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 45.16 | -- | -- | -- |
| Matinas BioPharma Holdings Inc | 0.00 | -16.87m | 3.66m | 3.00 | -- | 0.5225 | -- | -- | -3.30 | -3.30 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -111.43 | -49.82 | -126.56 | -54.00 | -- | -- | -- | -2,545.33 | -- | -- | 0.0025 | -- | -100.00 | -- | -5.71 | -- | -- | -- |
| Adial Pharmaceuticals Inc | 0.00 | -8.05m | 3.81m | 5.00 | -- | 0.7249 | -- | -- | -0.9289 | -0.9289 | 0.00 | 0.189 | 0.00 | -- | -- | 0.00 | -130.16 | -205.76 | -155.01 | -274.10 | -- | -- | -- | -- | -- | -27.38 | 0.00 | -- | -- | -- | -88.48 | -- | -- | -- |
| Silo Pharma Inc | 72.12k | -5.08m | 3.82m | -- | -- | 0.5994 | -- | 53.00 | -0.9262 | -0.9262 | 0.0117 | 0.4788 | 0.0097 | -- | -- | -- | -67.91 | -29.61 | -76.93 | -32.10 | 65.24 | 92.17 | -7,039.37 | -3,630.72 | -- | -- | 0.00 | -- | 0.00 | 12.19 | -20.98 | -- | -- | -- |
| Decoy Therapeutics Inc | 0.00 | -5.00m | 3.96m | 2.00 | -- | 0.1379 | -- | -- | -39.19 | -39.19 | 0.00 | 4.50 | 0.00 | -- | -- | 0.00 | -100.54 | -73.17 | -139.55 | -84.56 | -- | -- | -- | -987.44 | -- | -- | 0.00 | -- | -- | -- | 55.55 | -- | -- | -- |
| Bio Green Med Solution Inc | 81.00k | -6.97m | 4.07m | 12.00 | -- | 0.4093 | -- | 50.21 | -80.13 | -80.13 | 0.0775 | 2.03 | 0.012 | -- | 0.0821 | -- | -80.35 | -65.34 | -175.85 | -83.85 | 20.99 | -- | -6,714.82 | -17,774.73 | 5.07 | -241.39 | 0.00 | -- | -89.76 | -- | 50.73 | -- | -- | -- |
| ABPRO Holdings Inc | 0.00 | -22.04m | 4.07m | 6.00 | -- | -- | -- | -- | -24.37 | -24.37 | 0.00 | -6.04 | 0.00 | -- | -- | 0.00 | -467.23 | -- | -- | -- | -- | -- | -- | -- | -- | -4.82 | -- | -- | 50.00 | -- | -48.72 | -- | -- | -- |
| Shuttle Pharmaceuticals Holdings Inc | 0.00 | -10.71m | 4.21m | 9.00 | -- | 1.39 | -- | -- | -25.86 | -25.86 | 0.00 | 1.13 | 0.00 | -- | -- | 0.00 | -507.78 | -- | -3,614.50 | -- | -- | -- | -- | -- | -- | -- | 0.2305 | -- | -- | -- | -38.71 | -- | -- | -- |
| Dermata Therapeutics Inc | 0.00 | -8.85m | 4.22m | 8.00 | -- | 0.3774 | -- | -- | -28.37 | -28.37 | 0.00 | 4.69 | 0.00 | -- | -- | 0.00 | -150.49 | -136.32 | -203.36 | -201.56 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -57.64 | -- | -- | -- |
| Cyclerion Therapeutics Inc | 2.86m | -2.20m | 4.24m | 1.00 | -- | 0.4184 | -- | 1.48 | -0.7587 | -0.7587 | 1.00 | 2.58 | 0.2957 | -- | 39.65 | 2,855,000.00 | -22.77 | -53.70 | -24.80 | -63.57 | -- | -- | -77.02 | -1,913.83 | -- | -- | 0.00 | -- | -- | -15.00 | 75.72 | -- | -- | -- |
| Galmed Pharmaceuticals Ltd | 0.00 | -8.70m | 4.25m | 3.00 | -- | 0.1706 | -- | -- | -3.60 | -3.60 | 0.00 | 3.49 | 0.00 | -- | -- | 0.00 | -40.91 | -55.02 | -46.34 | -64.19 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.75 | -- | -- | -- |
| Acurx Pharmaceuticals Inc | 0.00 | -9.17m | 4.30m | 4.00 | -- | 1.02 | -- | -- | -8.54 | -8.54 | 0.00 | 2.02 | 0.00 | -- | -- | 0.00 | -151.72 | -158.12 | -291.07 | -208.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 3.26 | -- | -- | -- |
| Aprea Therapeutics Inc | 488.24k | -13.04m | 4.37m | 8.00 | -- | 0.3421 | -- | 8.94 | -2.14 | -2.14 | 0.08 | 1.95 | 0.0237 | -- | -- | 61,030.00 | -63.27 | -81.97 | -74.72 | -94.17 | -- | -- | -2,670.56 | -11,051.52 | -- | -- | 0.00 | -- | 157.63 | -- | 9.30 | -- | -12.91 | -- |
Data as of Feb 06 2026. Currency figures normalised to Silo Pharma Inc's reporting currency: US Dollar USD
11.62%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Anson Funds Management LPas of 30 Sep 2025 | 952.38k | 7.15% |
| AdvisorShares Investments LLCas of 30 Sep 2025 | 364.88k | 2.74% |
| Virtu Americas LLCas of 30 Sep 2025 | 107.79k | 0.81% |
| Geode Capital Management LLCas of 30 Sep 2025 | 39.60k | 0.30% |
| Jane Street Capital LLCas of 30 Sep 2025 | 16.77k | 0.13% |
| Two Sigma Securities LLCas of 30 Sep 2025 | 16.47k | 0.12% |
| StoneX Group, Inc. (Investment Management)as of 30 Sep 2025 | 13.43k | 0.10% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 13.10k | 0.10% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 12.50k | 0.09% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 11.22k | 0.08% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
